Man Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Man Group’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.59M	Sell	40,524 -86,662	-68%	-$4.5M	﹤0.01%	1444
2026 Q1	$6.12M	Buy	127,186 +87,739	+222%	+$3.89M	0.01%	1058
2025 Q4	$1.63M	Sell	39,447 -28,458	-42%	-$1.14M	﹤0.01%	1523
2025 Q3	$2.64M	Buy	+67,905	New	+$2.21M	﹤0.01%	1311
2025 Q2	–	Sell	-9,121	Closed	-$203K	–	2290
2025 Q1	$203K	Buy	+9,121	New	+$188K	﹤0.01%	2028
2024 Q4	–	Sell	-8,025	Closed	-$201K	–	2089
2024 Q3	$201K	Buy	+8,025	New	+$195K	﹤0.01%	1860
2021 Q4	–	Sell	-15,400	Closed	-$175K	–	2027
2021 Q3	$175K	Buy	+15,400	New	+$201K	﹤0.01%	1776

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Man Group's KNSA Position: Q2 2026 in Review

Man Group reduced its Kiniksa Pharmaceuticals (KNSA) stake by 68% in Q2 2026, selling an estimated $4.5M and leaving 40,524 shares worth $2.59M. The position accounts for ﹤0.01% of the portfolio, ranked #1444.

Man Group first reported a position in KNSA in Q3 2021 and has held it in 7 quarters since. The position peaked at $6.12M in Q1 2026. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Man Group held 40,524 shares of Kiniksa Pharmaceuticals worth $2.59M as of Q2 2026.
Man Group sold 86,662 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $4.5M.
Kiniksa Pharmaceuticals made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1444 holding.
Man Group first reported a position in Kiniksa Pharmaceuticals in Q3 2021 and has held it in 7 quarters since.
Man Group's Kiniksa Pharmaceuticals position peaked at $6.12M in Q1 2026.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.